• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mylan Pharmaceuticals Inc - Articles and news items

FDA to review Mylan and Biocon’s biosimilar application

Industry news / 17 February 2017 / Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has accepted Mylan and Biocon’s biologics license application for MYL-1401H, a proposed biosimilar to Neulasta…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

FDA accepts Mylan and Biocon’s biosimilar biologics license application

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers…

Mabion sign supply and commercialisation agreement with Mylan

Industry news / 10 November 2016 / Niamh Louise Marriott, Digital Content Producer

Mabion signed a long-term development and commercialisation agreement with Mylan Ireland a wholly owned subsidiary of Mylan N.V. for its biosimilar…

Mylan and Biocon submit FDA application for Trastuzumab biosimilar

Industry news / 9 November 2016 / Niamh Louise Marriott, Digital Content Producer

Mylan and Biocon have submitted a biologics license application for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA through the 351(K) pathway…

EMA accepts to review Mylan and Biocon’s cancer biosimilar

Industry news / 25 August 2016 / Niamh Louise Marriott, Digital Content Producer

Mylan and Biocon, who co-developed this proposed biosimilar, anticipate that this may be the first MAA for a trastuzumab biosimilar accepted by the EMA…

Phase 3 programme for revefenacin in COPD starts

Industry news / 14 September 2015 / Victoria White

The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study…

Mylan commences offer to acquire Perrigo

Industry news / 14 September 2015 / Victoria White

Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share…

Mylan shareholders approve proposed acquisition of Perrigo

Industry news / 28 August 2015 / Victoria White

Mylan’s proposed acquisition of Perrigo received the approval of two-thirds of the votes cast by Mylan shareholders at an extraordinary general meeting…

ISS recommends Mylan shareholders vote “against” Perrigo bid

Industry news / 17 August 2015 / Victoria White

The ISS has recommended that Mylan shareholders vote “against” the unsolicited offer to acquire all of the outstanding shares of Perrigo…

Teva withdraws proposal to acquire Mylan

Industry news / 28 July 2015 / Victoria White

Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan…

mylan

Mylan and Dr Reddy’s launch Memantine hydrochloride tablets in the US

Industry news / 15 July 2015 / Victoria White

Both Mylan and Dr. Reddy’s have launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, which is the generic version of Namenda Tablets, in the US…

  • Page 1 of 2
  • 1
  • 2
  • >